Switch theme
Sign up to access all valuation multiples
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
1998
2.7K+
LTM Revenue $22.4B
LTM EBITDA $8.1B
$11.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genmab has a last 12-month revenue (LTM) of $22.4B and a last 12-month EBITDA of $8.1B.
In the most recent fiscal year, Genmab achieved revenue of $469M and an EBITDA of $211M.
Genmab expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genmab valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $22.4B | XXX | $469M | XXX | XXX | XXX |
| Gross Profit | $21.2B | XXX | $447M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $8.1B | XXX | $211M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 45% | XXX | XXX | XXX |
| EBIT | $7.3B | XXX | $152M | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| Net Profit | $7.0B | XXX | $171M | XXX | XXX | XXX |
| Net Margin | 31% | XXX | 36% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Genmab's stock price is DKK 1498 (or $234).
Genmab has current market cap of DKK 92.1B (or $14.4B), and EV of DKK 74.5B (or $11.6B).
See Genmab trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.6B | $14.4B | XXX | XXX | XXX | XXX | $17.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Genmab has market cap of $14.4B and EV of $11.6B.
Genmab's trades at 24.8x EV/Revenue multiple, and 55.1x EV/EBITDA.
Equity research analysts estimate Genmab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genmab has a P/E ratio of 13.1x.
See valuation multiples for Genmab and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14.4B | XXX | $14.4B | XXX | XXX | XXX |
| EV (current) | $11.6B | XXX | $11.6B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 24.8x | XXX | XXX | XXX |
| EV/EBITDA | 9.2x | XXX | 55.1x | XXX | XXX | XXX |
| EV/EBIT | 10.2x | XXX | 76.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.1x | XXX | 84.2x | XXX | XXX | XXX |
| EV/FCF | 10.7x | XXX | 71.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenmab's last 12 month revenue growth is 13%
Genmab's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Genmab's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genmab's rule of X is 68% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genmab and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 198% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 209% | XXX | XXX | XXX |
| Rule of 40 | 49% | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 68% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genmab acquired XXX companies to date.
Last acquisition by Genmab was XXXXXXXX, XXXXX XXXXX XXXXXX . Genmab acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Genmab founded? | Genmab was founded in 1998. |
| Where is Genmab headquartered? | Genmab is headquartered in Denmark. |
| How many employees does Genmab have? | As of today, Genmab has 2.7K+ employees. |
| Who is the CEO of Genmab? | Genmab's CEO is Dr. Jan G. J. van de Winkel, PhD. |
| Is Genmab publicy listed? | Yes, Genmab is a public company listed on CSE. |
| What is the stock symbol of Genmab? | Genmab trades under GMAB ticker. |
| When did Genmab go public? | Genmab went public in 2000. |
| Who are competitors of Genmab? | Similar companies to Genmab include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Genmab? | Genmab's current market cap is $14.4B |
| What is the current revenue of Genmab? | Genmab's last 12 months revenue is $22.4B. |
| What is the current revenue growth of Genmab? | Genmab revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Genmab? | Current revenue multiple of Genmab is 3.3x. |
| Is Genmab profitable? | Yes, Genmab is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genmab? | Genmab's last 12 months EBITDA is $8.1B. |
| What is Genmab's EBITDA margin? | Genmab's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Genmab? | Current EBITDA multiple of Genmab is 9.2x. |
| What is the current FCF of Genmab? | Genmab's last 12 months FCF is $7.0B. |
| What is Genmab's FCF margin? | Genmab's last 12 months FCF margin is 31%. |
| What is the current EV/FCF multiple of Genmab? | Current FCF multiple of Genmab is 10.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
